Luka Vončina

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications

Alessandra Ferrario, Diāna Arāja, Tomasz Bochenek et al. · PharmacoEconomics · 2017 · 121 citations · Full text

Public Affairs, Pharmaceutical Policy, Health Technology Assessment +8

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

Rickard E. Malmström, Brian Godman, Eduard Diogène et al. · Frontiers in Pharmacology · 2013 · 91 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future

Luka Vončina, Tihomir Strizrep, Brian Godman et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2011 · 83 citations

Pharmacy, Cardiology, Pharmacology +17

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Brian Godman, Andrew Hill, Steven Simoens et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2021 · 73 citations · Full text

Pharmacy, Oncology, Pharmaceutical Policy +17

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

Evelien Moorkens, Brian Godman, Isabelle Huys et al. · Frontiers in Pharmacology · 2021 · 68 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacology +17